vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and VIAVI SOLUTIONS INC. (VIAV). Click either name above to swap in a different company.
VIAVI SOLUTIONS INC. is the larger business by last-quarter revenue ($406.8M vs $177.4M, roughly 2.3× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 1.6%, a 0.1% gap on every dollar of revenue. On growth, VIAVI SOLUTIONS INC. posted the faster year-over-year revenue change (42.8% vs 5.0%). Over the past eight quarters, VIAVI SOLUTIONS INC.'s revenue compounded faster (27.1% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Viavi Solutions Inc., formerly part of JDS Uniphase Corporation (JDSU), is an American network test, measurement and assurance technology company based in Chandler, Arizona. The company manufactures testing and monitoring equipment for networks. It also develops optical technology used for a range of applications including material quality control, currency anti-counterfeiting and 3D motion sensing, including Microsoft's Kinect video game controller.
PCRX vs VIAV — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $406.8M |
| Net Profit | $2.9M | $6.4M |
| Gross Margin | — | 57.5% |
| Operating Margin | 3.9% | 6.1% |
| Net Margin | 1.6% | 1.6% |
| Revenue YoY | 5.0% | 42.8% |
| Net Profit YoY | — | -76.1% |
| EPS (diluted) | $0.07 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $406.8M | ||
| Q4 25 | $196.9M | $369.3M | ||
| Q3 25 | $179.5M | $299.1M | ||
| Q2 25 | $181.1M | $290.5M | ||
| Q1 25 | $168.9M | $284.8M | ||
| Q4 24 | $187.3M | $270.8M | ||
| Q3 24 | $168.6M | $238.2M | ||
| Q2 24 | $178.0M | $252.0M |
| Q1 26 | $2.9M | $6.4M | ||
| Q4 25 | — | $-48.1M | ||
| Q3 25 | $5.4M | $-21.4M | ||
| Q2 25 | $-4.8M | $8.0M | ||
| Q1 25 | $4.8M | $19.5M | ||
| Q4 24 | — | $9.1M | ||
| Q3 24 | $-143.5M | $-1.8M | ||
| Q2 24 | $18.9M | $-21.7M |
| Q1 26 | — | 57.5% | ||
| Q4 25 | 79.5% | 57.0% | ||
| Q3 25 | 80.9% | 56.5% | ||
| Q2 25 | 77.4% | 56.3% | ||
| Q1 25 | 79.7% | 56.4% | ||
| Q4 24 | 78.7% | 59.4% | ||
| Q3 24 | 76.9% | 57.1% | ||
| Q2 24 | 75.1% | 57.8% |
| Q1 26 | 3.9% | 6.1% | ||
| Q4 25 | 1.2% | 3.1% | ||
| Q3 25 | 3.5% | 2.5% | ||
| Q2 25 | 4.7% | 5.3% | ||
| Q1 25 | 1.2% | 3.0% | ||
| Q4 24 | 13.2% | 8.2% | ||
| Q3 24 | -82.8% | 4.8% | ||
| Q2 24 | 15.9% | -2.3% |
| Q1 26 | 1.6% | 1.6% | ||
| Q4 25 | — | -13.0% | ||
| Q3 25 | 3.0% | -7.2% | ||
| Q2 25 | -2.7% | 2.8% | ||
| Q1 25 | 2.8% | 6.8% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | -85.1% | -0.8% | ||
| Q2 24 | 10.6% | -8.6% |
| Q1 26 | $0.07 | $0.03 | ||
| Q4 25 | $0.05 | $-0.21 | ||
| Q3 25 | $0.12 | $-0.10 | ||
| Q2 25 | $-0.11 | $0.03 | ||
| Q1 25 | $0.10 | $0.09 | ||
| Q4 24 | $0.38 | $0.04 | ||
| Q3 24 | $-3.11 | $-0.01 | ||
| Q2 24 | $0.39 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $500.8M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $653.9M | $846.5M |
| Total Assets | $1.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.28× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $500.8M | ||
| Q4 25 | $238.4M | $767.4M | ||
| Q3 25 | $246.3M | $545.6M | ||
| Q2 25 | $445.9M | $425.3M | ||
| Q1 25 | $493.6M | $396.8M | ||
| Q4 24 | $484.6M | $509.4M | ||
| Q3 24 | $453.8M | $493.1M | ||
| Q2 24 | $404.2M | $491.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $372.2M | $1.2B | ||
| Q3 25 | $376.7M | $640.5M | ||
| Q2 25 | $580.5M | $396.3M | ||
| Q1 25 | $583.4M | $396.1M | ||
| Q4 24 | $585.3M | $639.3M | ||
| Q3 24 | — | $637.6M | ||
| Q2 24 | — | $636.0M |
| Q1 26 | $653.9M | $846.5M | ||
| Q4 25 | $693.1M | $834.3M | ||
| Q3 25 | $727.2M | $723.9M | ||
| Q2 25 | $757.8M | $780.2M | ||
| Q1 25 | $798.5M | $728.8M | ||
| Q4 24 | $778.3M | $682.8M | ||
| Q3 24 | $749.6M | $702.1M | ||
| Q2 24 | $879.3M | $681.6M |
| Q1 26 | $1.2B | $2.5B | ||
| Q4 25 | $1.3B | $2.8B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.5B | $2.0B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.6B | $1.7B |
| Q1 26 | — | 1.28× | ||
| Q4 25 | 0.54× | 1.46× | ||
| Q3 25 | 0.52× | 0.88× | ||
| Q2 25 | 0.77× | 0.51× | ||
| Q1 25 | 0.73× | 0.54× | ||
| Q4 24 | 0.75× | 0.94× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
VIAV
Segment breakdown not available.
